

OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-05 11:30:02

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Foot and mouth disease
Address of laboratory:	14 rue Pierre et Marie Curie F-94700 Maisons-Alfort Cedex FRANCE
Tel.:	+33 (0)1 49 77 13 17
Fax:	+33 (0)1 49 77 38 25
E-mail address:	labib.bakkali-kassimi@anses.fr
Website:	www.anses.fr
Name (including Title) of Head of Laboratory (Responsible Official):	Pascal BOIREAU
Name (including Title and Position) of OIE Reference Expert:	Bakkali Kassimi Labib
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
ELISA NSP	Oui	176	47
ELISA SP	Oui	180	47
Séroneutralisation	Oui	3	48
Direct diagnostic tests		Nationally	Internationally
Isolement viral	Oui	2	2
RT-qPCR	Oui	12	50
RT-PCR	Non	0	4

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
kit	ELISA NSP	PrioCHECK FMD NS	0	8	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Kit	ELISA SP	PrioCHECK FMD Type O	0	6	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Amorces de détection et typage	RT-PCR	Oligonucléotides	0	0,2ml (200 réactions)	1	<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Master Mix RTqPCR	RTqPCR	Solution prés à l'emploi	0	6 ml (300 réaction)	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new

procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

Yes

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

Name of the new test or diagnostic method or vaccine developed	Description and References (Publication, website, etc.)
Triplex One-Step rtRT-PCR for FMDV detection	Publication en cours

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
MAURITIUS	Mars	47	18

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
MAURITIUS	Vaccination	Par email

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Validation du protocole d'inactivation des LFD par l'acide citrique en vue d'envoi des échantillons au laboratoire sans risque biologique et à moins coût	2 ans	Validation du protocole sur le terrain à partir de prélèvements frais	NVRI;SAP;UM;FLI;DTU;BI;ANSES	GERMANY DENMARK FRANCE NIGERIA PAKISTAN TURKEY
Des signatures protéogénomiques de la réponse de l'hôte à l'infection persistante par le virus de la fièvre aphteuse (FMDV) aux marqueurs de diagnostic et au contrôle thérapeutique	3 ans	Déterminer les mécanismes et les facteurs susceptibles de contribuer à la prévention ou au contrôle des infections persistantes et à l'amélioration des diagnostics	FLI; SLU; Sciensano; SAP; Anses	GERMANY BELGIUM FRANCE SWEDEN TURKEY
Préparation et réponse aux pathogènes d'importance médicale et vétérinaire dans un contexte d'urgence importance médicale et vétérinaire	3 ans	Mettre en place une plateforme portable de diagnostic par séquençage capable de fournir dans un délai cliniquement pertinent des informations critiques dans le contexte d'une épidémie.	FLI; BNITM; ANSES; AMU	GERMANY FRANCE

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Réapparition du virus O-Ind2001 à l'île Rodrigue

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
Réapparition du virus O-Ind2001 à l'île Rodrigue

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 1
Réunion des laboratoires de référence OIE/FA pour la fièvre aphteuse

c) National conferences: 0

d) Other:
(Provide website address or link to appropriate information) 0

***ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards***

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 0
b) Seminars: 0
c) Hands-on training courses: 3
d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
C	Algérie, Mauritanie, Maroc, Tunisie	14
C	Bulgarie, Grèce, Macédoine du Nord, Monténégro, Serbie, Turquie, Ukraine,	15
C	Arménie, Azerbaïdjan, Géorgie, Iraq, Pakistan, Turquie	20

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	Attestation 1-2246 révision 20.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
RTqPCR	COFRAC
ELISA	COFRAC

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: ¹	Role of your Reference Laboratory (organiser/participant)	No. participants	Participating OIE Ref. Labs/organising OIE Ref. Lab.
Validation méthode	Organisateur	10	Pirbright, Sciensano/Anses

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Développement d'une one-tp RTqPCR pour la détection de FMDV A/G-IV	Développement de méthode de détection spécifique de A/G-IV	Pirbright, Sciensano
Analyse phylogéographique de FMDV O/EA-3	Identification des voies de diffusion du topotype O/EA-3 du virus de la fièvre aphteuse en Afrique et en Asie occidentale entre 1974 et 2019	Pirbright, Sciensano, IZSLER

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Evaluer la capacité de diagnostic sérologique et virologique	40	<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Observateur	Réunion Virtuelle	3rd GF-TADs West Africa Roadmap Meeting for foot-and-mouth disease
Observateur	Réunion Virtuelle	5th GF-TADs Middle East Roadmap and 2nd Epidemiology and Laboratory Networks Meeting for Foot-and-Mouth Disease
Présentateur	Réunion Virtuelle	22th JPC/REMESA 2021

25. Additional comments regarding your report:

L'épidémie du Covid-19 a eu un impact significatif sur les activités de référence et d'expertise